Literature DB >> 23585494

Prognostic significance of changes in serum thyroglobulin antibody levels of pre- and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients.

Yukiko Tsushima1, Akira Miyauchi, Yasuhiro Ito, Takumi Kudo, Hiroo Masuoka, Tomonori Yabuta, Mitsuhiro Fukushima, Minoru Kihara, Takuya Higashiyama, Yuuki Takamura, Kaoru Kobayashi, Akihiro Miya, Toyone Kikumori, Tsuneo Imai, Tetsuya Kiuchi.   

Abstract

Although postoperative serum thyroglobulin (Tg) is a prognostic indicator for papillary thyroid carcinoma (PTC), it is unreliable when Tg antibody (TgAb) is positive. We evaluated the prognostic significance of changes in serum TgAb levels of pre- and post-total thyroidectomy in TgAb-positive PTC patients. We reviewed our medical charts of 225 TgAb-positive PTC patients in whom TgAb levels were measured before and 1-2 years after total thyroidectomy, performed between April 2002 and March 2007. We divided them into 3 groups based on changes in TgAb levels. Postoperative serum TgAb levels decreased by ≥ 50% in 181 patients (80.4%) (Group 1), by <50% in 22 patients (9.8%) (Group 2), and increased in 22 patients (9.8%) (Group 3). During the follow-up, 3 patients died of the disease and 14 patients had recurrences. All 3 patients who died of PTC were seen only in Groups 2 and 3. Groups 2 and 3 showed similar prognostic outcomes, thus were analyzed together as Group 2+3. Group 1 had significantly better lymph node recurrence-free survival and distant recurrence-free survival than Group 2+3 (96.9% vs. 90.5%, p <0.001, and 98.9% vs. 90.1%, p = 0.004, respectively at 5 years). Multivariate analyses on prognostic factors revealed that classification to Group 2+3 was the strongest indicator for poor prognosis. The present results suggest that changes in TgAb levels following total thyroidectomy can be an important dynamic prognostic factor of PTC patients. Prospective periodical measurements of TgAb are necessary to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23585494     DOI: 10.1507/endocrj.ej12-0410

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  12 in total

1.  Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies.

Authors:  Cosimo Durante; Sara Tognini; Teresa Montesano; Fabio Orlandi; Massimo Torlontano; Efisio Puxeddu; Marco Attard; Giuseppe Costante; Salvatore Tumino; Domenico Meringolo; Rocco Bruno; Fabiana Trulli; Maria Toteda; Adriano Redler; Giuseppe Ronga; Sebastiano Filetti; Fabio Monzani
Journal:  Thyroid       Date:  2014-05-21       Impact factor: 6.568

2.  Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma.

Authors:  Hee Jeong Park; Geum-Cheol Jeong; Seong Young Kwon; Jung-Joon Min; Hee-Seung Bom; Ki Seong Park; Sang-Geon Cho; Sae-Ryung Kang; Jahae Kim; Ho-Chun Song; Ari Chong; Su Woong Yoo
Journal:  Nucl Med Mol Imaging       Date:  2014-06-28

3.  Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation.

Authors:  Yasuhiro Ito; Akira Miyauchi; Minoru Kihara; Takuya Higashiyama; Kaoru Kobayashi; Akihiro Miya
Journal:  Thyroid       Date:  2013-11-14       Impact factor: 6.568

4.  Prevalence and Significance of Thyroglobulin Antibodies in Pediatric Thyroid Cancer.

Authors:  Ari J Wassner; Margaret Della Vecchia; Petr Jarolim; Henry A Feldman; Stephen A Huang
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

5.  Relationship Between Thyroid Autoantibodies and Recurrence of Papillary Thyroid Carcinoma in Children and Adolescents.

Authors:  Dongmei Huang; Jingtai Zhi; Jinming Zhang; Xuan Qin; Jingzhu Zhao; Xiangqian Zheng; Ming Gao
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

6.  Prognostic value of change in anti-thyroglobulin antibodies after thyroidectomy in patients with papillary thyroid carcinoma.

Authors:  A Ernaga-Lorea; M C Hernández-Morhain; E Anda-Apiñániz; J J Pineda-Arribas; I Migueliz-Bermejo; N Eguílaz-Esparza; A Irigaray-Echarri
Journal:  Clin Transl Oncol       Date:  2017-10-25       Impact factor: 3.405

7.  Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications.

Authors:  Carole Spencer; Ivana Petrovic; Shireen Fatemi; Jonathan LoPresti
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

8.  Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer.

Authors:  Fernanda Bueno; María Gabriela García Falcone; Mirna Angela Peñaloza; Erika Abelleira; Fabián Pitoia
Journal:  Endocrine       Date:  2019-10-24       Impact factor: 3.633

Review 9.  How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies.

Authors:  Carole Spencer; Jonathan LoPresti; Shireen Fatemi
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

10.  Antithyroglobulin Antibody as a Marker of Successful Ablation Therapy in Differentiated Thyroid Cancer.

Authors:  Ayu Rosemeilia Dewi; Budi Darmawan; Achmad Hussein Sundawa Kartamihadja; Basuki Hidayat; Johan S Masjhur
Journal:  World J Nucl Med       Date:  2017 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.